Biotech Adam Feuerstein STAT Plus: In study, Gilead’s Trodelvy shows modest benefit in breast cancer patients
Biotech Adam Feuerstein STAT Plus: The FDA’s Pazdur on accelerated approval, single-arm studies, and his own future
Health Matthew Herper Weight loss from bariatric surgery is associated with a reduced risk of cancer in study
Pharma Adam Feuerstein STAT Plus: Radioactive drug helps men with advanced prostate cancer, but survival benefit is debated
Health Matthew Herper STAT Plus: AstraZeneca drug prevents breast cancer caused by BRCA mutations from returning
Biotech Matthew Herper STAT Plus: In a step forward for immunotherapy, new Bristol Myers drug slows melanoma in study
Adam's Take Adam Feuerstein STAT Plus: ASCO 2020 takeaways: AstraZeneca does a star turn, KRAS fizzles, and cell therapy shows progress
Biotech Matthew Herper STAT Plus: With the right molecular signal, a cancer drug works in every patient
Pharma Adam Feuerstein STAT Plus: Roche’s TIGIT troubles escalate, sparking more debate about the closely tracked cancer immunotherapy target
Biotech Angus Chen STAT Plus: Promising results reported for new generation of CAR-T immunotherapy for myeloma
Biotech Matthew Herper STAT Plus: Enhertu, a smart bomb drug, dramatically extends survival in breast cancer patients
Biotech Adam Feuerstein STAT Plus: With new data on its KRAS-blocking lung cancer drug, Mirati expects to take on a rival Amgen treatment
Biotech Adam Feuerstein STAT Plus: Fate Therapeutics’ natural killer cells induce responses in blood cancer patients, but for how long?
Pharma Adam Feuerstein STAT Plus: For first time, immunotherapy after surgery shows benefit for patients with early kidney cancer
Biotech Adam Feuerstein STAT Plus: Allogene’s blood cancer data show durability of off-the-shelf CAR-T cells
Pharma Adam Feuerstein STAT Plus: With new data, J&J’s CAR-T drug benefits myeloma patients with less advanced disease
Biotech Adam Feuerstein STAT Plus: Merus drug shows potential as treatment for rare type of pancreatic cancer
First Opinion Maura McCarthy Early diagnosis, not cancer drug breakthroughs, is the best way to fix the global scourge of breast cancer
Biotech Adam Feuerstein STAT Plus: Additional blood cancer responses seen with Allogene’s off-the-shelf CAR-T cells, updated study shows
Biotech Adam Feuerstein STAT Plus: AstraZeneca study results could change treatment for certain early-stage lung cancer patients
Biotech Adam Feuerstein STAT Plus: Roche’s novel checkpoint inhibitor delivers mixed results in new lung cancer study
Biotech Adam Feuerstein STAT Plus: Some blood cancer patients see remission with Allogene’s off-the-shelf CAR-T cells, early data show
The Readout LOUD Adam Feuerstein and Matthew Herper Listen: A special episode from the halls of the ASCO meeting
Biotech Adam Feuerstein and Matthew Herper STAT Plus: What you missed at ASCO? A lot, as cancer research hastens on
Biotech Adam Feuerstein STAT Plus: At ASCO, targeted lung cancer drugs shrink tumors caused by rare genetic mutations
Biotech Matthew Herper STAT Plus: Tempus, a well-funded company run by a Groupon billionaire, wants to get patients into clinical trials
Biotech Adam Feuerstein STAT Plus: Amgen’s drug — targeting an ‘undruggable’ cancer protein — shrank tumors in half of patients
Health Matthew Herper The Affordable Care Act erased a racial disparity in cancer care, a new study says
Pharma Matthew Herper STAT Plus: Forget controversy. AstraZeneca’s dynamic duo wants to dominate the market for cancer drugs
Biotech Matthew Herper STAT Plus: Novartis hopes new survival data will help its Kisqali take on Pfizer’s Ibrance. It probably won’t